Drug Shortage Report for MYLAN-EMTRICITABINE/TENOFOVIR DISOPROXIL
Report ID | 114152 |
Drug Identification Number | 02443902 |
Brand name | MYLAN-EMTRICITABINE/TENOFOVIR DISOPROXIL |
Common or Proper name | EMTRICITABINE/TENOFOVIR DISOPROXIL |
Company Name | MYLAN PHARMACEUTICALS ULC |
Market Status | MARKETED |
Active Ingredient(s) | TENOFOVIR DISOPROXIL FUMARATE EMTRICITABINE |
Strength(s) | 300MG 200MG |
Dosage form(s) | TABLET |
Route of administration | ORAL ORAL |
Packaging size | 30BT |
ATC code | J05AR |
ATC description | DIRECT ACTING ANTIVIRALS |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | 2020-07-10 |
Actual start date | |
Estimated end date | 2020-07-28 |
Actual end date | 2020-05-11 |
Shortage status | Avoided shortage |
Updated date | 2020-05-12 |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 85 ADVANCE ROAD ETOBICOKE, ONTARIO CANADA M8Z 2S6 |
Company contact information | Mylan Pharmaceuticals ULC, 85 Advance Road, Etobicoke, ON, M8Z 2S6 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v4 | 2020-05-12 | French | Compare |
v3 | 2020-05-12 | English | Compare |
v2 | 2020-05-06 | French | Compare |
v1 | 2020-05-06 | English | Compare |
Showing 1 to 4 of 4